

Since late 2024, we have been aligned with ABL, Inc. Together we offer scalable support for specialty advanced therapeutic developers from research to commercialization with United States and European locations.
Ascend can support your journey at any scale for:
Gene therapies
Immunotherapies
Oncolytics
Vaccines

Development Based Expertise
All our work comes from a background of developing therapies. When we struggled to find our own CDMOs, we became one. Discover the difference of working with a team with deep chemistry, manufacturing & controls (CMC).
Decades of Biologics, Innovation & Expertise
60+ years custom biologics & vaccines support with 20+ AAV development expertise
Next gen technologies & analytics complemented by deep regulatory acumen
Onsite fill-finish capabilities in multiple US locations
Latest News & Insights
2 June 2025
Accelerating LVV Process Development with Fast, Precise Titer Determination – Part 2
Overcoming the Limitations of Current LVV Titer Measurement As described in Part One of this blog series, quantification of...
Read More2 June 2025
Accelerating LVV Process Development with Fast, Precise Titer Determination
Growing demand for lentiviral vectors (LVVs) is creating the need for robust, scalable, GMP manufacturing processes. Accelerating process development...
Read More5 March 2025
Ascend Advanced Therapies Appoints John Chiminski as Chair & Karen Flynn as Independent Director
Rockville, MD – March 5, 2025 – Ascend Advanced Therapies (Ascend), a gene to GMP advanced therapy development partner,...
Read More3 February 2025
Polo-like kinase inhibitors increase AAV production by halting cell cycle progression
Recombinant adeno-associated viruses (rAAVs) are commonly used in gene therapy for preclinical research and therapeutic applications. Despite the clinical...
Read MoreTake your career to a new level with Ascend
Email us at hello@ascend-adv.com to share your enthusiasm and expertise and one of our team will be in touch.
